Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: A cost-of-illness study (LINCE study)

Sancho, Jerónimo; Peña, Pilar de la; Rufo, M; Palacios, Gregorio Pérez; Masramon, Xavier; Rejas, Javier

doi:10.1016/j.eplepsyres.2008.05.008

Cited by 41 publications

(26 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cost data literature review resulted in 33 relevant cost studies identified for 11 disorders (Table 2): anxiety disorder [23], dementia [24]–[31], epilepsy [32], [33], headache [15], [34], [35], mood disorders [36]–[40], multiple sclerosis [14], [41]–[43], Parkinson's disease [24], [44], psychotic disorders [45], [46], stroke [24], [47]–[50] and neuromuscular diseases [51]. Two articles were excluded from de model because they presented outlier estimations for stroke [52], [53] and traumatic brain injury [52].…”

Section: Resultsmentioning

confidence: 99%

Cost of Disorders of the Brain in Spain

et al. 2014

View full text Add to dashboard Cite

BackgroundBrain disorders represent a high burden in Europe and worldwide. The objective of this study was to provide specific estimates of the economic costs of brain disorders in Spain, based on published epidemiological and economic evidence.MethodsA cost-of-illness study with a societal perspective of 19 brain disorders was carried out. Cost data published between 2004 and 2012 was obtained from a systematic literature review. Direct healthcare, direct non-medical and indirect costs were considered, prioritizing bottom-up information. All costs were converted to Euro and to year 2010. The missing values were imputed with European estimates. Sensitivity analyses based on qualitative assessment of the literature and on a Monte Carlo simulation were performed.ResultsThe review identified 33 articles with information on costs for 11 disorders (8 neurological, 3 mental). The average per–patient cost ranged from 36,946 € for multiple sclerosis to 402 € for headache. The societal cost of the 19 brain disorders in Spain in 2010 was estimated in 84 € billion. Societal costs ranged from 15 € billion for dementia to 65 € million for eating disorders. Mental disorders societal cost were 46 € billions (55% of the total), while neurological disorder added up to 38 € billion. Healthcare costs represented 37% of the societal costs of brain disorders, whereas direct non-medical constituted 29% and indirect costs 33%.ConclusionBrain disorders have a substantial economic impact in Spain (equivalent to almost 8% of the country's GDP). Economic data on several important brain disorders, specially mental disorders, is still sparse.

show abstract

Section: Resultsmentioning

confidence: 99%

Cost of Disorders of the Brain in Spain

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Another possible limitation could be the novelty of the SATMED-Q instrument. However, this instrument has already been used successfully in large cohorts of patients with refractory epilepsy and resistant antihypertensive therapy to measure patients' satisfaction with medicines [58,59] .…”

Section: Discussionmentioning

confidence: 99%

Current Treatments of Alzheimer Disease: Are Main Caregivers Satisfied with the Drug Treatments Received by Their Patients?

Sevilla

Caballero²,

Alfonso³

et al. 2009

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Background/Aims: A full comparison of the satisfaction with treatment using the current Alzheimer’s disease (AD) therapies from the perspective of caregivers has not yet been done. The aim of this study was thus to find out the degree of satisfaction with the main available drug treatments in monotherapy for AD from this point of view. Methods: A cross-sectional, multicentre study of patients with possible/probable AD according to DSM-IV/NINCDS-ADRDA criteria, on monotherapy with donepezil, galantamine, rivastigmine or memantine, was carried out. Treatment satisfaction was measured by a caregiver proxy-administration of the generic SATMED-Q questionnaire [range: 0 (not satisfied at all) to 100 (totally satisfied)], overall and in 6 domains: tolerability, efficacy, medical care, ease and convenience, impact on daily activities and overall satisfaction. Results: A total of 829 patients were included: 63.3% women, aged 78.2 ± 6.8 years; 546 (67.3%) on donepezil, 106 (13.1%) on rivastigmine, 99 (12.2%) on galantamine and 60 (7.4%) on memantine. SATMED-Q scores p values were adjusted by MMSE and treatment duration. Caregivers of patients on donepezil showed significantly higher SATMED-Q total (71.8 ± 12.3; p < 0.05) and overall satisfaction domain scores (81.6 ± 18.4; p < 0.01) than those of patients on any other drugs, as well as significantly higher ease and convenience of use domain (81.5 ± 17.4; p < 0.01) and undesirable effects domain (96.0 ± 12.9; p < 0.05) scores than those of rivastigmine- and galantamine-treated patients. Of the caregivers of donepezil-treated patients, 76.7% were satisfied with treatment versus 68.7, 61.4 and 46.7% of those caregivers whose patients were treated with galantamine, rivastigmine and memantine, respectively (p = 0.0002). Conclusion: Caregivers of AD patients undergoing donepezil monotherapy seem to be more satisfied with treatment than those of patients receiving the other usual AD treatments in this study, particularly due to the ease and convenience of use of this drug. The higher level of satisfaction of these caregivers could be explained by the fact that, within the donepezil group, a high percentage of patients were treated with orally disintegrating tablets, which are easier for the patient to swallow.

show abstract

“…Studies of the economic effects of epilepsy have focused primarily on model information, questionnaires, and other direct or indirect information in selected groups of patients (primarily adults), and estimates of the economic burden extracted from this information . There is a small amount of information from long‐term prospective studies in children, which indicates a significant socioeconomic impact of the disorder .…”

mentioning

confidence: 99%

Long‐term socioeconomic consequences and health care costs of childhood and adolescent‐onset epilepsy

Jennum

Christensen

Ibsen³

et al. 2016

Epilepsia

View full text Add to dashboard Cite

SUMMARYObjective: To estimate long-term socioeconomic consequences and health care costs of epilepsy with onset in childhood and adolescence. Methods: A historical prospective cohort study of Danish individuals with epilepsy, age up to 20 years at time of diagnosis between January 1981 and December 2012. Information about marital status, parenthood, educational level, employment status, income, use of the health care system, and cost of medicine was obtained from nationwide administrative and health registers. Results: We identified 12,756 and 28,319 people with diagnosed with epilepsy, ages 0-5 and 6-20 years at onset, respectively. Using follow-up data for a maximum of 30 years, 1,394 of those ages 0-5 years at onset were compared with 2,897 controls persons without epilepsy, and 10,195 of those ages 6-20 years at onset were compared with 20,678 controls without epilepsy. Compared with people without the epilepsy, those with epilepsy tended to have a lower level of education, to be less likely to be married, to be more likely to live alone, and to have higher divorce and unemployment rates, lower employment rates, and people with epilepsy were more likely to receive disability pension and social security. Income was lower from employment, which in part was compensated by social security, sick pay, disability pension and unemployment benefit, sick pay (publicfunded), disability pension, and other public transfers. Predicted health care costs 30 years after epilepsy onset were significantly higher among persons with epilepsy onset at 0-5 and 6-20 years, including costs for outpatient and inpatient services (hospital services), emergency room use, primary health care sector (general practice), and use of medication. Significance: The long-term negative effects on all aspects of health care and social domains, including marital status, parental socioeconomic status, educational level, employment status, and use of welfare benefits compared with controls without epilepsy calls for increased awareness on childhood-and adolescentonset epilepsy.

show abstract

Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: A cost-of-illness study (LINCE study)

Cited by 41 publications

References 38 publications

Cost of Disorders of the Brain in Spain

Cost of Disorders of the Brain in Spain

Current Treatments of Alzheimer Disease: Are Main Caregivers Satisfied with the Drug Treatments Received by Their Patients?

Long‐term socioeconomic consequences and health care costs of childhood and adolescent‐onset epilepsy

Contact Info

Product

Resources

About